title: Management of diabetes in patients with cancer.
abstract: Diabetes is common amongst patients with cancer. The co-occurrence of diabetes and cancer may lead to poorer prognosis and complications in patients undergoing cancer therapy. There is no randomized trial evidence that treating hyperglycaemia in patients with cancer improves outcomes, and therefore a pragmatic approach to managing hyperglycaemic in such patients is required. We discuss the management of hyperglycaemia in relation to cancer chemotherapy, glucocorticoids and enteral feeding. We also discuss management of glucose in diabetic patients with cancer approaching end of life care.
authors.affiliation: From the Department of Diabetes and Metabolism, Barts and the London School of Medicine and Dentistry, London, UK.
authors.forename: P
authors.initials: P
authors.lastname: Jacob
authors.affiliation: From the Department of Diabetes and Metabolism, Barts and the London School of Medicine and Dentistry, London, UK tahseen.chowdhury@bartshealth.nhs.uk.
authors.forename: T A
authors.initials: TA
authors.lastname: Chowdhury
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000517:prevention & control*; D004750:Enteral Nutrition; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D011379:Prognosis; D013727:Terminal Care / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D005938:Glucocorticoids; D007004:Hypoglycemic Agents